NEW YORK, Feb. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leader in microwave ablation (MWA) technology, made a significant impact at the 2025 North American Society for Interventional Thyroidology (NASIT) conference. Building on the success of its NASIT 2024 participation, Baird Medical returned to this premier event to engage with industry leaders and showcase the clinical advantages of its cutting-edge MWA technology for thyroid treatment.

NASIT 2025

Baird Medical's exhibit drew strong interest, sparking in-depth discussions with clinicians about the future of minimally invasive thyroid therapies. The Company provided expert insights into MWA's efficacy and safety in treating thyroid nodules, addressing key concerns from physicians. Hands-on demonstrations allowed attendees to experience the technology's precision and efficiency firsthand, further reinforcing Baird Medical's leadership in the field.

A highlight of the conference was a keynote presentation by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University School of Medicine. Dr. Kandil shared compelling case studies and clinical data demonstrating MWA's role as a safe, effective, and minimally invasive alternative to traditional thyroid surgery. He emphasized key benefits, including reduced procedure times, fewer complications, and improved patient outcomes. The session attracted a large audience and ignited dynamic discussions, highlighting the industry's strong interest in MWA technology and providing robust support for Baird Medical's vision of minimally invasive treatment.

Baird Medical's presence at NASIT 2025 reaffirmed its commitment to advancing patient care through innovation. By deepening collaborations with medical professionals, the Company continues to drive progress in minimally invasive thyroid treatments. Looking ahead, Baird Medical aims to leverage further research breakthroughs and strategic partnerships to enhance treatment options for patients and propel advancements in minimally invasive therapies.

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.